Related Experiment Video
Updated: Jun 1, 2026
Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model
Published on: September 8, 2023
Efficacy of serotonin inhibition in mouse models of bone loss
Hiroyuki Inose1, Bin Zhou, Vijay K Yadav
1Departments of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA.
Abstract:
In a proof-of-concept study it was shown that decreasing synthesis of gut serotonin through a small molecule inhibitor of Tph1 could prevent and treat ovariectomy-induced osteoporosis in young mice and rats. In this study, we define the minimal efficacy of this Tph1 inhibitor, demonstrate that its activity is improved with the duration of treatment, and show that its anabolic effect persists on interruption. Importantly, given the prevalence of osteoporosis in the aging population, we then show that Tph1 inhibition rescues ovariectomy-induced bone loss in aged mice. It also cures the low bone mass of Lrp5-deficient mice through a sole anabolic effect. Lastly, we provide evidence that inhibition of gut serotonin synthesis can work in concert with an antiresorptive agent to increase bone mass in ovariectomized mice. This study provides a more comprehensive view of the anabolic efficacy of Tph1 inhibitors and further establishes the spectrum of their therapeutic potential in the treatment of bone-loss disorders.
Insights
Inhibiting gut serotonin synthesis with a Tph1 inhibitor prevents and treats osteoporosis. This approach demonstrates anabolic effects in young and aged mice, offering new therapeutic potential for bone-loss disorders.
Area of Science:
- Biomedical Research
- Pharmacology
- Bone Biology
Background:
- Osteoporosis is a prevalent condition, particularly in aging populations.
- Gut serotonin, synthesized via Tryptophan hydroxylase 1 (Tph1), influences bone metabolism.
- Previous studies suggested Tph1 inhibition as a potential osteoporosis treatment.
Purpose of the Study:
- To comprehensively evaluate the anabolic efficacy of Tph1 inhibitors for bone-loss disorders.
- To define the minimal efficacy and treatment duration effects of a Tph1 inhibitor.
- To assess Tph1 inhibition in aged and genetically modified mouse models of low bone mass.
Main Methods:
- Administration of a Tph1 inhibitor in young and aged ovariectomized mice.
- Assessment of bone mass and anabolic effects following Tph1 inhibition.
- Evaluation of Tph1 inhibitor efficacy in Lrp5-deficient mice.
- Combination therapy with an antiresorptive agent.
Main Results:
- Tph1 inhibition demonstrated efficacy in preventing and treating ovariectomy-induced osteoporosis in young and aged mice.
- The anabolic effect of Tph1 inhibition persisted after treatment interruption and improved with treatment duration.
- Tph1 inhibition successfully rescued bone mass in Lrp5-deficient mice.
- Combined treatment with an antiresorptive agent enhanced bone mass.
Conclusions:
- Tph1 inhibitors possess significant anabolic efficacy for treating bone-loss disorders.
- Gut serotonin inhibition represents a promising therapeutic strategy for osteoporosis.
- Tph1 inhibition offers a broad therapeutic potential for various bone-loss conditions.
